1. Intussusception and Other Adverse Event Surveillance after Pilot Introduction of Rotavirus Vaccine in Nam Dinh and Thua Thien Hue Provinces—Vietnam, 2017–2021
- Author
-
Ly Khanh Thi Le, Thao Phuong Thi Pham, Le Thi Phuong Mai, Quyet Tu Nguyen, Mai Phuong Ngoc Tran, Thien Huu Ho, Hung Hoang Pham, Sanh Van Le, Ha Ngoc Hoang, Anh Tuan Lai, Nguyen Thuy Huong, Hien Dang Nguyen, Dang Duc Anh, Makiko Iijima, Umesh D. Parashar, Nguyen Van Trang, and Jacqueline E. Tate
- Subjects
rotavirus ,intussusception ,Rotavin-M1 vaccine ,safety ,adverse events following immunization (AEFI) ,Medicine - Abstract
Rotavin-M1 (POLYVAC) was licensed in Vietnam in 2012. The association of Rotavin-M1 with intussusception, a rare adverse event associated with rotavirus vaccines, and with adverse events following immunization (AEFI) have not been evaluated and monitored under conditions of routine use. From February 2017 to May 2021, we conducted a pilot introduction of Rotavin-M1 into the routine vaccination program in two provinces. Surveillance for intussusception was conducted at six sentinel hospitals. AEFI reports at 30 min and 7 days after vaccination were recorded. Among 443 children ®, ComBE Five®) compared to Rotavin-M1 without pentavalent vaccines. There was no association between intussusception and Rotavin-M1. The vaccine was generally safe when administered alone and when co-administered with other vaccines.
- Published
- 2024
- Full Text
- View/download PDF